June 27, 2014 / 1:07 PM / in 4 years

Nordion-Sterigenics deal faces U.S. regulatory delay

TORONTO, June 27 (Reuters) - The takeover of Nordion Inc , the Canadian medical isotope supplier, has run into a speed bump as U.S. antitrust regulators requested further information from Nordion and its suitor Sterigenics, in order to approve the deal.

In a brief statement on Friday, Nordion said it has received a request for additional information from the U.S. Federal Trade Commission under the Hart-Scott-Rodino Act. The “Second Request” extends the waiting period imposed by the act until 30 days after Nordion and Sterigenics have complied with the request.

Nordion, a leading producers of molybdenum-99, an isotope used in medical imaging, said it still expects the $805 million deal to close in the second half of 2014.

Sterigenics, a sterilization services provider owned by private equity firm GTCR LLC, twice sweetened its bid for Nordion in order to clinch a deal, after Nordion twice received rival proposals from an unnamed buyer. (Reporting by Euan Rocha; Editing by Jeffrey Benkoe)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below